The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Open accessAbstract
BACKGROUND: Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in-class cardiac myosin inhibitor, may lower gradients and improve symptoms in these patients. OBJECTIVES: This study aims to evaluate the safety and efficacy of aficamten in patients with oHCM. METHODS: Patients with oHCM and LVOT gradients ≥30 mm Hg at rest or ≥50 mm Hg with Valsalva were randomized 2:1 to receive aficamten (n = 28) or placebo (n = 13) in 2 dose-finding cohorts. Doses were titrated based on gradients and ejection fraction (EF). Safety and changes in gradient, EF, New York Heart Association functional class, and cardiac biomarkers were assessed over a 10-week treatment period and after a 2-week washout. RESULTS: From baseline to 10 weeks, aficamten reduced gradients at rest (mean difference: -40 ± 27 mm Hg, and -43 ± 37 mm Hg in Cohorts 1 and 2, P = 0.0003 and P = 0.0004 vs placebo, respectively) and with Valsalva (-36 ± 27 mm Hg and -53 ± 44 mm Hg, P = 0.001 and <0.0001 vs placebo, respectively). There were modest reductions in EF (-6% ± 7.5% and -12% ± 5.9%, P = 0.007 and P < 0.0001 vs placebo, respectively). Symptomatic improvement in ≥1 New York Heart Association functional class was observed in 31% on placebo, and 43% and 64% on aficamten in Cohorts 1 and 2, respectively (nonsignificant). With aficamten, N-terminal pro-B-type natriuretic peptide was reduced (62% relative to placebo, P = 0.0002). There were no treatment interruptions and adverse events were similar between treatment arms. CONCLUSIONS: Aficamten resulted in substantial reductions in LVOT gradients with most patients experiencing improvement in biomarkers and symptoms. These results highlight the potential of sarcomere-targeted therapy for treatment of oHCM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
Self-citationOlivotto, I., Oreziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A., Garcia-Pavia, P., Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31792-x · Cited by 1,296
Self-citationSherrid, M. V., Shetty, A., Winson, G., Kim, B., Musat, D., Alviar, C. L., Homel, P., Balaram, S. K., & Swistel, D. G. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000122 · Cited by 178
Cited by
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Self-citationOmmen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K. C., Evanovich, L., Ferrari, V. A., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001250 · Cited by 807
Self-citation2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
Ommen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K. C., Evanovich, L., Ferrari, V. A., et al. (2024) · JACC · doi:10.1016/j.jacc.2024.02.014 · Cited by 382
Self-citationAficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Maron, M. S., Masri, A., Nassif, M. E., Barriales-Villa, R., Arad, M., Cardim, N., Choudhury, L., Claggett, B., Coats, C. J., Düngen, H.-D., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401424 · Cited by 348
Self-citationHegde, S. M., Claggett, B. L., Wang, X., Jering, K., Prasad, N., Roshanali, F., Masri, A., Nassif, M. E., Barriales-Villa, R., Abraham, T. P., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.002 · Cited by 47
Self-citation
Metadata
- Authors
- Maron, M. S., Masri, A., Choudhury, L., Olivotto, I., Saberi, S., Wang, A., Garcia-Pavia, P., Lakdawala, N. K., Nagueh, S. F., Rader, F., Tower-Rader, A., Turer, A. T., Coats, C., Fifer, M. A., Owens, A., Solomon, S. D., Watkins, H., Barriales-Villa, R., Kramer, C. M., Wong, T. C., Paige, S. L., Heitner, S. B., Kupfer, S., Malik, F. I., Meng, L., Wohltman, A., & Abraham, T.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 81
- Issue
- 1
- Pages
- 34-45
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W4313429960
- Cited by
- 204
- References
- 3
- FWCI
- 35.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. https://app.cochat.ai/papers/10.1016/j.jacc.2022.10.020
- The paper
- Maron, M. S., Masri, A., Choudhury, L., Olivotto, I., Saberi, S., Wang, A., Garcia-Pavia, P., Lakdawala, N. K., Nagueh, S. F., Rader, F., Tower-Rader, A., Turer, A. T., Coats, C., Fifer, M. A., Owens, A., Solomon, S. D., Watkins, H., Barriales-Villa, R., Kramer, C. M., . . . Abraham, T. (2023). Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2022.10.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.